Aging and enhanced hepatocarcinogenicity by peroxisome proliferator- activated receptor alpha agonists

Ageing Research Reviews

Volumn 4, Issue 1, 2005, Pages 103-118

  Youssef, Jihan A ^a   Badr, Mostafa Z ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Apoptosis; Hepatocarcinogenicity; Kupffer cells; Oxidative stress; PPARs

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; REGULATOR PROTEIN;

AGING; ANTIOXIDANT ACTIVITY; APOPTOSIS; CARCINOGENESIS; CARCINOGENICITY; CELL CYCLE; CELL PROLIFERATION; CORRELATION ANALYSIS; DNA DAMAGE; DNA REPLICATION; ENZYME ACTIVITY; HUMAN; KUPFFER CELL; LIVER CANCER; LIVER CARCINOGENESIS; LIVER INJURY; LIVER TUMOR; NONHUMAN; OXIDATIVE STRESS; REVIEW;

ANIMALIA;

EID: 11144296372     PISSN: 15681637     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arr.2004.10.002     Document Type: Short Survey

References (97)

1. M. Badr, and L. Birnbaum Selective induction of peroxisomal enzyme activities by perfluorooctanoic acid in aged rats Toxicologist 187 1991 11 [Abstract]
2. M. Badr Peroxisome proliferator-activated receptor alpha and cancer: friends or foes? Int J. Cancer Prev. 1 3 2004 77 87
3. M. Badr, and L. Birnbaum Enhanced potential for oxidative stress in livers of senescent rats by the peroxisome proliferator-activated receptor alpha agonist perfluorooctanoic acid Mech. Ageing Dev. 125 2004 69 75
4. Y. Barak, D. Liao, W. He, E.S. Ong, M.C. Nelson, J.M. Olefsky, R. Boland, and R.M. Evans Effects of peroxisome proliferator-activated receptor delta on placentation, adiposity, and colorectal cancer Proc. Natl. Acad. Sci. U.S.A. 99 2002 303 308
5. K. Beier, A. Volkl, and H. Fahimi The impact of aging on enzyme proteins of rat liver peroxisomes-quantitative analysis by immunoblotting and immunoelectron microscopy Virchows Arch. B 63 1993 139 146
6. P. Bentley, C. Elcombe, P. Grasso, D. Stringer, and H. Wiegand Hepatic peroxisome proliferation in rodents and its significance for humans Fd. Chem. Toxicol. 31 1993 857 907
7. J. Berger, and D. Moller The mechanisms of action of PPARs Annu. Rev. Med. 53 2002 409 435
8. H.K. Bojes, D.R. Germolec, P. Simeonova, A. Bruccoleri, R. Schoonhoven, M.I. Luster, and R.G. Thurman Antibodies to tumor necrosis factor alpha prevent increases in cell replication in liver due to the potent peroxisome proliferator, WY-14,643 Carcinogenesis 18 1997 669 674
9. R. Brun, P. Tontonoz, B. Forman, R. Ellis, J. Chen, R. Evans, and B. Spiegelman Differential activation of adipogenesis by multiple PPAR isoforms Gene Dev. 10 1996 974 984
10. R.C. Cattley, D.S. Marsman, and J.A. Popp Age-related susceptibility to the carcinogenic effect of the peroxisome proliferator Wy-14,643 in rat liver Carcinogenesis 12 1991 469 473
11. C. Chao, J. Youssef, M. Rezaiekhaleigh, L. Birnbaum, and M. Badr Senescence-associated decline in hepatic peroxisomal enzyme activities corresponds with diminished levels of retinoid X receptor alpha, but not peroxisome proliferator-activated receptor alpha Mech. Ageing Dev. 123 2002 1469 1476
12. G. Chinetti, J.C. Fruchart, and B. Staels Peroxisome proliferator- activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation Inflamm. Res. 49 2000 497 505
13. R. Dei, A. Takeda, H. Niwa, M. Li, Y. Nakagomi, T. Watanabe, Y. Washimi, Y. Yasuda, K. Horie, T. Miyata, and G. Sobue Lipid peroxidation and advanced glycation end products in the brain in normal aging and in Alzheimer's disease Acta Neuropathol. 104 2002 113 122
14. P. Delerive, J.C. Fruchart, and B. Staels Peroxisome proliferator- activated receptors in inflammation control J. Endocrinol. 169 2001 453 459
15. B. Desvergne, and W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr. Rev. 20 1999 649 688
16. P. Eacho, P. Foxworthy, W. Johnson, D. Hoover, and S. White Hepatic peroxisomal changes induced by a tetrazole-substituted alkoxyacetophenone in rats and comparison with other species Toxicol. Appl. Pharmacol. 83 1986 430 437
17. B.M. Forman, J. Chen, and R.M. Evans Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta Proc. Natl. Acad. Sci. U.S.A. 94 1997 4312 4317
18. 2-induced hepatic oxidant injury in aged rats FASEB J. 4 1982 A302
19. B. Fringes, and A. Reith Time-course of peroxisome biogenesis during adaptation to mild hyperthyroidism in rat liver Lab. Invest. 47 1982 19 26
20. B. Fringes, A. Reith, and U. Riede Peroxisome biogenesis in rat liver during adaptation to mild hyperthyroidism: a morphometric/stereologic study by electron microscopy Ann. NY Acad. Sci. 386 1982 514 518
21. A. Galli, M. Stewart, R. Dorris, and D. Crabb High-level expression of RXRα and presence of endogenous ligands contribute to expression of a peroxisome proliferators-activated responsive gene in hepatoma cells Arch. Biochem. Biophys. 354 1998 288 294
22. B. Gilver, D. Alberts, G. Wollenberg, M. Pitzenberger, J. DeLuca, and J. Lawrence TNFα is not required for Wy-14,643-induced proliferation in mice Toxicologist 54 2000 A1975
23. W. Goll, E. Alexandre, C. Viollon-Abadie, L. Nicod, D. Jaeck, and L. Richert Comparison of the effects of various peroxisome proliferators on peroxisomal enzyme activities, DNA synthesis, and apoptosis in rat and human hepatocyte cultures Toxicol. Appl. Pharmacol. 160 1999 21 32
24. J.L. Haining, and J.S. Legan Catalase turnover in rat liver and kidney as a function of age Exp. Gerontol. 8 1973 85 91
25. B. Halliwell, and J. Gutteridge Role of free radicals and catalytic metal ions in human disease: an overview Methods Enzymol. 186 1990 1 85
26. M. Hanefeld, C. Kemmer, and E. Kadner Relationship between morphological changes and lipid-lowering action of p-chlorophenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man Atherosclerosis 46 1983 239 246
27. N. Harvey, and S. Kumar The role of caspases in apoptosis Adv. Biochem. Eng. Technol. 62 1998 107 128
28. P. Holden, S. Hasmall, N. James, D. West, R. Brindle, F. Gonzalez, J. Peters, and R. Roberts Tumor necrosis factor α (TNFα): role in suppression of apoptosis by the peroxisome proliferator nafenopin Cell Mol. Biol. 46 2000 29 39
29. S. Horie, H. Ishii, and T. Suga Changes in peroxisomal fatty acid oxidation in the diabetic rat liver J. Biochem. 90 1981 1691 1696
30. W. Huber, B. Kraupp-Grasl, H. Esterbauer, and R. Schulte-Hermann Role of oxidative stress in age-dependent hepatocarcinogenesis by the peroxisome proliferator nafenopin in the rat Cancer Res. 51 1991 1789 1792
31. W. Huber, B. Kraupp-Grasl, and R. Schulte-Hermann Hepatocarcinogenic potential of di(2-ethylhexyl)phthalate in rodents and its implications on human risk Crit. Rev. Toxicol. 26 1996 365 481
32. I. Issemann, and S. Green Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators Nature 347 1990 645 650
33. L. Jackson, W. Wahli, L. Michalik, S. Watson, K. Anderton, D. Bell, J. Smith, C. Hawkey, and A. Bennett Potential role for peroxisome proliferator activated receptor (PPAR) in preventing colon cancer Gut 52 2003 1317 1322
34. W.G. Karam, and B.I. Ghanayem Induction of replicative DNA synthesis and PPAR alpha-dependent gene transcription by Wy-14 643 in primary rat hepatocyte and non-parenchymal cell co-cultures Carcinogenesis 18 1997 2077 2083
35. J. Klaunig, M. Babich, K. Baetcke, J. Cook, C. Corton, R. David, J. DeLuca, D. Lai, R. McKee, J. Peters, R. Roberts, and P. Fenner-Crisp PPARa agonist-induced rodent tumors: modes of action and human relevance Crit. Rev. Toxicol. 33 2003 655 780
36. S. Kliewer, S. Sundseth, S. Jones, P. Brown, G.B. Wisely, C. Koble, P. Devchand, W. Wahli, T. Willson, J. Lenhard, and J. Lehman Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ Proc. Natl. Acad. Sci. U.S.A. 94 1997 4318 4323
37. B. Kraupp-Grasl, W. Huber, H. Taper, and R. Schulte-Hermann Increased susceptibility of aged rats to hepatocarcinogenesis by the peroxisome proliferator nafenopin and the possible involvement of altered liver foci occurring spontaneously Cancer Res. 51 1991 666 671
38. B. Lake, J. Evans, T. Gray, S. Korosi, and C. North Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, syrian hamster, guinea pig and marmoset Toxicol. Appl. Pharmacol. 99 1989 148 160
39. J. Lawrence, G. Wollenberg, and J. DeLuca Tumor necrosis factor alpha is not required for Wy-14,643-induced cell proliferation Carcinogenesis 22 2001 381 386
40. B.J. Ledwith, S. Manam, P. Troilo, D.J. Joslyn, S.M. Galloway, and W.W. Nichols Activation of immediate-early gene expression by peroxisome proliferators in vitro Mol. Carcinog. 8 1993 20 27
41. B.J. Ledwith, T.E. Johnson, L.K. Wagner, C.J. Pauley, S. Manam, S.M. Galloway, and W.W. Nichols Growth regulation by peroxisome proliferators: opposing activities in early and late G1 Cancer Res. 56 1996 3257 3264
42. S.S. Lee, T. Pineau, J. Drago, E.J. Lee, J.W. Owens, D.L. Kroetz, P.M. Fernandez-Salguero, H. Westphal, and F.J. Gonzalez Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators Mol. Cell. Biol. 15 1995 3012 3022
43. A-M. Lefebvre, M. Laville, N. Vega, J. Riou, L. Gaal, J. Auwerx, and H. Vidal Depot-specific differences in adipose tissue gene expression in lean and obese subjects Diabetes 47 1998 98 103
44. E. Levy, R. Slusser, and B. Ruebner Hepatic changes produced by a single dose of endotoxin in the mouse Am. J. Pathol. 52 1968 477 502
45. H. Lim, R. Gupta, W-G. Ma, B. Paria, D. Moller, J. Morrow, R. DuBois, J. Trzaskos, and S. Dey Cyclooxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARδ Gene Dev. 13 1999 1561 1574
46. C. Masters, and D. Crane On the Role of the peroxisome in ontogeny, aging and degenerative disease Mech. Ageing Dev. 80 1995 69 83
47. L. Michalik, and W. Wahli Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions Curr. Opin. Biotechnol. 10 1999 564 570
48. R. Miller, S. Glover, W. Stewart, J. Corton, J. Popp, and R. Cattley Effect on the expression of c-met, c-myc and PPARα in liver and liver tumors from rats chronically exposed to the hepatocarcingenic peroxisome proliferator WY-14,643 Carcinogenesis 17 1996 1337 1341
49. D.E. Moody, J.K. Reddy, B.G. Lake, J.A. Popp, and D.H. Reese Peroxisome proliferation and nongenotoxic carcinogenesis: commentary on a symposium Fundam. Appl. Toxicol. 16 1991 233 248
50. J. Morrow, and L. Roberts II The isoprostanes: current knowledge and directions for future research Biochem. Pharmacol. 51 1996 1 9
51. α-inducible genes, lower triglycerides and raise HDL levels in vivo Arterioscler. Thromb. Vasc. Biol. 18 1998 272 276
52. C. Neat, M. Thomassen, and H. Osmundsen Induction of peroxisomal β-oxidation in rat liver by high fat diet Biochemistry 186 1980 369 371
53. M. O'Brien, S. Rangwala, K. Henry, C. Weinberger, D. Crick, C. Waecher, D. Feller, and D. Noonan Convergence of three steroid receptor pathways in the mediation of nongenotoxic hepatocarcinogenesis Carcinogenesis 17 1996 185 190
54. F. Oesch, L. Schladt, P. Steinberg, and H. Thomas Concomitant induction of cytosolic epoxide hydrolase and peroxisomal β-oxidation by hypolipidemic compounds in rat and guinea pig liver Arch. Toxicol. 12 Suppl. 1988 248 255
55. R. Perichon, and J.M. Bourre Peroxisomal β-oxidation activity and catalase activity during development and aging in mouse liver Biochimie 77 1995 288 293
56. R. Perichon, and J.M. Bourrem Age-related decrease in liver peroxisomal fatty acid oxidation in control and clofibrate-treated mice. A biochemical study and mechanistic approach Mech. Ageing Dev. 87 1996 115 126
57. J.M. Peters, R.C. Cattley, and F.J. Gonzalez Role of PPAR alpha in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643 Carcinogenesis 18 1997 2029 2033
58. J. Peters, T. Aoyama, R. Cattley, U. Nobumitsus, T. Hashimoto, and F. Gonzzalez Role of peroxisome proliferator-activated receptor alpha in altered cell cycle regulation in mouse liver Carcinogenesis 19 1998 1989 1994
59. J. Peters, I. Rusyn, M. Rose, F. Gonzalez, and R. Thurman Peroxisome proliferators-activated receptor α is restricted to hepatic parenchymal cells, not kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis Carcinogenesis 21 2000 823 826
60. J.K. Reddy, and N. Lalwani Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans Crit. Rev. Toxicol. 12 1983 1 58
61. J.L. Rigatuso, P.G. Legg, and R.L. Wood Microbody formation in regenerating rat liver J. Histochem. Cytochem. 18 1970 893 900
62. R. Roberts, N. James, N. Woodyatt, N. Macdonald, and J. Tugwood Evidence for the suppression of apoptosis by the peroxisome proliferator-activated receptor alpha (PPARα) Carcinogenesis 19 1998 43 48
63. R. Roberts, N. James, P. Hasmall, P. Holden, K. Lambe, N. Macdonald, D. West, N. Woodyatt, and D. Whitcome Apoptosis and proliferation in nongenotoxic carcinogenesis: species differences and role of PPARα Toxicol. Lett. 112-113 2000 49 57
64. M. Rolfe, N.H. James, and R.A. Roberts Tumour necrosis factor alpha (TNF alpha) suppresses apoptosis and induces DNA synthesis in rodent hepatocytes: a mediator of the hepatocarcinogenicity of peroxisome proliferators? Carcinogenesis 18 1997 2277 2280
65. M. Rose, I. Rusyn, H. Bojes, D. Germolec, M. Luster, and R. Thurman Role of kupffer cells in peroxisome proliferators-induced hepatocyte proliferation Drug Metab. Rev. 31 1999 87 116
66. I. Rusyn, H. Tsukamoto, and R. Thurman Wy-14,643 rapidly activates nuclear factor κB in Kupffer cells Carcinogenesis 19 1998 1217 1222
67. I. Rusyn, Y. Yamashina, B. Segal, R. Schoonhoven, S. Hollard, R. Cattley, J. Swenberg, and R. Thurman Oxidants from nicotinamide adenine dinucleotide phosphate oxidase are involved in triggering cell proliferation in the liver due to peroxisome proliferators Cancer Res. 60 2000 4798 4803
68. M. Sakuma, J. Yamada, and T. Suga Comparison of the inducing effect of dehydroepiandrosterone on hepatic peroxisome proliferation-associated enzymes in several rodent species Biochem. Pharmacol. 43 1992 1269 1273
69. M. Sawada, and J.C. Carlson Changes in superoxide radical and lipid peroxide formation in the brain, heart and liver during the lifetime of the rat Mech. Ageing Dev. 41 1987 125 137
70. I. Semsei, G. Rao, and A. Richardson Changes in the expression of superoxide dismutase and catalse as a function of age and dietary restriction Biochem. Biophys. Res. Commun. 164 1989 620 625
71. P. Southorn, and G. Powis Free radicals in medicine. Part II. Involvement in human disease Mayo Clin. Proc. 63 1988 390 408
72. B. Spiegelman PPARγ in monocytes: less pain, any gain Cell 93 1998 153 155
73. B. Spiegelman, and J. Flier Adipogenesis and obesity: rounding out the big picture Cell 87 1996 377 389
74. W. Staubli, F. Hess, and E. Weibel Correlated morphometric and biochemical studies on the rat liver cell. Part II. Effects of phenobarbital on rat hepatocytes J. Cell. Biol. 42 1969 92 112
75. K. Suchanek, F. May, J. Robinson, W. Lee, N. Holman, G. Monteith, and S. Roberts-Thomson Peroxisome proliferator-activated receptor α in the human breast cancer cell lines MCF-7 and MDA-MB-231 Mol. Carcinog. 34 2002 165 171
76. Y. Suh, K. Lee, W. Kim, B. Han, J. Vijg, and S. Park Aging alters the apoptotic response to genotoxic stress Nat. Med. 8 2002 3 4
77. B. Taylor, N. Dadia, C. Yang, S. Krishnan, and M. Badr Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia Inflammation 26 2002 121 127
78. H. Thomas, L. Schladt, M. Knehr, and F. Oesch Effect of diabetes and starvation on the activity of rat liver epoxide hydrolase, glutathione-S transferase and peroxisomal β-oxidation Biochem. Pharmacol. 38 1989 4291 4297
79. N. Thornberry, and Y. Lazabnik Caspases: enemies within Science 281 1998 312 316
80. M. Tsai, and B. O'Malley Molecular mechanisms of action of steroid/thyroid receptor superfamily members Annu. Rev. Biochem. 63 1994 451 486
81. C. Wang, J. Youssef, B. Saran, P. Rothberg, M. Cunningham, A. Molteni, and M. Badr Diminished energy metabolism and enhanced apoptosis in livers of B6C3F1 mice treated with the antihepatocarcinogen rotenone Mol. Cell. Biochem. 201 1999 25 32
82. T. Watanabe, S. Horie, J. Yamada, M. Isaji, T. Nishigaki, J. Naito, and T. Suga Species differences in the effect of bezafibrate, a hypolipidemic agent, on hepatic peroxisome-associated enzymes Biochem. Pharmacol. 38 1989 367 371
83. T. Willson, P. Brown, D. Sternbach, and B. Henke The PPARs: from orphan receptors to drug discovery J. Med. Chem. 43 2000 527 550
84. K. Uchimura, M. Nakamuta, M. Enjoji, T. Irie, R. Sugimoto, T. Muta, H. Iwamoto, and H. Hawata Activation of retinoic X receptor and peroxisome proliferator-activated receptor-γ inhibits nitric oxide and tumor necrosis factor-α production in rat Kupffer cells Hepatology 33 2001 91 99
85. R. Van den Munckhof, K. Bosch, and W. Frederiks The different effects of the peroxisome proliferators clofibric acid and bis(2-ethylhexyl)phthalate on the activities of peroxisomal oxidases in rat liver Histochem. J. 30 1998 339 349
86. J.P. Vanden Heuvel Peroxisome Proliferator-activated receptors (PPARS) and carcinogenesis Toxicol. Sci. 47 1999 1 8
87. A. Vidal-Puig, R. Considine, M. Jimenez-Linan, A. Werman, W. Porries, J. Caro, and J. Flier Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss and regulation by insulin and glucocorticoids J. Clin. Invest. 99 1997 2416 2422
88. E. Xia, G. Rao, H. Van Remmen, A. Heydari, and A. Richardson Activities of antioxidant enzymes in various tissues of male Fischer 344 rats are altered by food restriction J. Nutr. 125 1995 195 201
89. T. Yamoto, Y. Ohashi, M. Teranishi, M. Takaoka, S. Manabe, N. Matsunuma, and T. Makita Age-related changes in the susceptibility to clofibric acid, a hypolipidemic agent, of male rat liver Toxicol. Lett. 78 1995 141 145
90. J. Youssef, and M. Badr Activated kupffer cells attenuate the liver response to the peroxisome proliferator perfluorooctanoic acid Mol. Cell. Biochem. 169 1997 143 147
91. J. Youssef, and M. Badr Extraperoxisomal targets of peroxisome proliferators. Mitochondrial, microsomal and cytosolic effects. Implication for health and disease CRC Crit. Rev. Toxicol. 28 1998 1 33
92. J. Youssef, and M. Badr Biology of senescent liver peroxisomes: role in hepatocellular aging and disease Environ. Health Perspect. 107 1999 791 797
93. J. Youssef, and M. Badr Peroxisomal alterations in aging and disease M. Mattson Interorganellar Signaling in Age-Related Disease, Advances in Cell Aging and Gerontology vol. 28 2001 Elsevier Press 1 28
94. J. Youssef, and M. Badr Peroxisome proliferator-activated receptors: from orphnage to fame in a decade Saudi Pharm. J. 9 2002 1 13
95. J. Youssef, and M. Badr Enhanced hepatotoxicity due to agonists of peroxisome proliferator-activated receptors in senescent rats. Role of peroxisome proliferation, cell proliferation and apoptosis Scientific World J. 2 2002 1491 1500
96. J. Youssef, M. Bouziane, and M. Badr Age-dependent effects of nongenotoxic hepatocarcinogens on liver apoptosis in vivo Mech. Ageing dev. 124 2003 335 342
97. J. Youssef, and M. Badr Role of peroxisome proliferator-activated receptors in inflammation control J. Biomed. Biotech. 2004 2004 156 166